NCT06361979View on ClinicalTrials.gov

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2026

Conditions
Breasr Cancer
Interventions
DRUG

SHR-A1811

SHR-A1811: intravenous

DRUG

Bevacizumab

Bevacizumab:intravenous

All Listed Sponsors
lead

Huihua Xiong

OTHER

NCT06361979 - SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases | Biotech Hunter | Biotech Hunter